Is BMY or BRNS more undervalued in 2026?

CirclFi compares Bristol-Myers Squibb Company (BMY) and Barinthus Biotherapeutics plc (BRNS) using 13 institutional-grade valuation models. BMY has a Quality of Company score of 9.9/10 while BRNS scores 6.0/10.

Which is a better buy — BMY or BRNS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do BMY and BRNS valuations compare?

BMY at $57.18 and BRNS at $0.68 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

BMY vs BRNS Valuation Comparison 2026 — Intrinsic Value Analysis

BMY

Pharmaceutical Preparations

Bristol-Myers Squibb Company

Quality

9.9

out of 10

Value Trap

SAFE

Price

$57.18

Last close

Models

12/13

Active

BRNS

Pharmaceutical Preparations

Barinthus Biotherapeutics plc

Quality

6.0

out of 10

Value Trap

SAFE

Price

$0.68

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	BMY Fair Value	BMY Upside	BRNS Fair Value	BRNS Upside
Bayesian DCF	Intrinsic	$122.58	+114.4%	$0.94	+38.4%
Earnings Power Value	Intrinsic	$52.56	-8.1%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$129.41	+126.3%	$0.29	-57.0%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for BMY vs BRNS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BMY vs BRNS — Which Stock Is More Undervalued?

BMY scores higher with a 9.9/10 quality rating vs BRNS's 6.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Bristol-Myers Squibb Company (BMY) and Barinthus Biotherapeutics plc (BRNS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BMY currently trades at $57.18 with a QOC of 9.9/10, while BRNS trades at $0.68 with a QOC of 6.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).